Orexo AB (publ) (STO:ORX)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 673.99M |
| Revenue (ttm) | 26.00M |
| Net Income (ttm) | 639.30M |
| Shares Out | 34.92M |
| EPS (ttm) | 18.46 |
| PE Ratio | 1.05 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,565 |
| Average Volume | 49,563 |
| Open | 19.76 |
| Previous Close | 19.92 |
| Day's Range | 18.16 - 19.76 |
| 52-Week Range | 13.56 - 43.40 |
| Beta | 0.96 |
| RSI | 35.33 |
| Earnings Date | Apr 28, 2026 |
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Orexo AB Transcript: R&D Day
AmorphOX technology is the core focus, driving a pipeline of late-stage and exploratory projects in nasal and oral drug delivery, including OX640, OX390, and IZIPRY. Strategic partnerships, robust funding, and a disciplined R&D approach position the company for key milestones and commercial opportunities over the next several years.
Invitation & Agenda: Orexo R&D Day on March 24
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026.
Orexo changes the organizational structure and management team to increase focus on development of new products
UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team.
Orexo AB Earnings Call Transcript: Q4 2025
Divestment of Zubsolv U.S. business brought a major cash infusion and strategic refocus on the AmorphOX platform. Continued operations are well-capitalized, with key pipeline projects advancing and a two-year runway expected.
Orexo AB Transcript: Investor Update
U.S. rights to Zubsolv were sold to Dexcel Pharma for $91 million plus potential earn-outs, enabling debt redemption and funding for pipeline projects. Organizational changes include U.S. staff transfer and streamlined operations, while the company focuses on advancing its development pipeline and partnering opportunities.
Orexo AB Earnings Call Transcript: Q3 2025
Q3 saw strong R&D progress, especially in GLP-1 and OX390, with BARDA funding secured for the latter. Revenue declined year-over-year due to FX and contract impacts, but gross margin improved and 2025 positive EBITDA guidance is reaffirmed.
Orexo AB Transcript: Investing in Life Science 2025
Sales remain strong with positive EBITDA, driven by Zubsolv and a robust U.S. presence. The pipeline features innovative nasal delivery products and the AmorphOX platform, which enables stable, high-bioavailability formulations for both small and large molecules. Partnership discussions and market adaptation are ongoing.
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared wi...
Orexo AB Earnings Call Transcript: Q2 2025
Q2 results were impacted by a one-time SEK 9 million rebate and negative FX, but core U.S. business remained stable with improved margins and cost control. Pipeline progress continued for OX124 (IC3) and OX640, and 2025 guidance was reaffirmed.
Orexo to present clinical data for OX640 at the EAACI Congress
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology EAACI is a ...
Orexo AB Earnings Call Transcript: Q1 2025
Q1 delivered stable revenues and positive EBITDA, with Zubsolv sales steady despite volume declines from payer policy changes. OX640 attracted strong partner interest after a successful trial, and 2025 guidance was reaffirmed.
Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations te...
Orexo AB Earnings Call Transcript: Q4 2024
Full-year and Q4 EBITDA turned positive, driven by cost reductions and stable U.S. sales. Litigation resolution and asset restructuring improved strategic flexibility, while digital assets were impaired due to regulatory hurdles. OX124 FDA resubmission faces supplier delays.
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vacci...
Orexo initiates new study of OX640 in participants with allergic rhinitis
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.
Orexo AB Earnings Call Transcript: Q3 2024
Q3 saw Zubsolv stabilize in demand and commercial growth, but revenues declined due to public segment and FX. OX124 approval was delayed by FDA data requests, and legal uncertainties persist. 2024 guidance is maintained, with a strategic review underway and positive EBITDA expected.
Orexo´s Nomination Committee for the Annual General Meeting 2025
UPPSALA, Sweden , Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the f...
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
UPPSALA, Sweden , Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.
Orexo AB Earnings Call Transcript: Q2 2024
Q2 2024 saw a rebound in Zubsolv sales and positive EBITDA, but OX124 approval was delayed by an FDA CRL requiring more device data. Abstral royalties declined as contracts expired, while European Zubsolv revenues grew. Financial guidance for 2024 is maintained amid ongoing legal and regulatory uncertainties.
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Ad...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provi...
Orexo: invitation to presentation of the Q2 2024 Interim Report
UPPSALA, Sweden , July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm, analysts, ...
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
UPPSALA, Sweden , May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social...